DOCSLIB.ORG

The Genetics of Heterotaxy Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Genetics of Heterotaxy Syndrome The Genetics of Heterotaxy Syndrome A dissertation submitted to the Division of Graduate Studies and Research, University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular and Developmental Biology by Jason R. Cowan Master of Science, University of British Columbia, Vancouver, 2007 Committee Chair: Stephanie M. Ware, M.D., Ph.D. Robert B. Hinton Jr., M.D. Linda M. Parysek, Ph.D. S. Steven Potter, Ph.D. Aaron M. Zorn, Ph.D. Molecular & Developmental Biology Graduate Program College of Medicine, University of Cincinnati Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio, USA, 2015 ABSTRACT Congenital heart defects (CHDs) are the greatest cause of infant morbidity and mortality worldwide, occurring in roughly 8 per 1000 live births (~1%). Heterotaxy, a multiple congenital anomaly syndrome resulting from failure to establish left-right (L-R) asymmetry, is characterized by diverse, complex CHDs. Heterogeneous in presentation and etiology, heterotaxy serves as a complex and growing focal point for cardiovascular genetic research. In the two decades since the zinc finger transcription factor, ZIC3, was first identified as a cause of X-linked heterotaxy, mutations in nearly twenty genes with L-R patterning functions have been detected among patients with heterotaxy. Nevertheless, despite considerable progress, genetic causes for heterotaxy remain largely uncharacterized. With an estimated 70-80% of heterotaxy cases still unexplained, there remains enormous potential for novel gene discovery. In this dissertation, we have balanced gene discovery efforts aimed at identifying and characterizing novel causes of heterotaxy with studies into the mechanisms governing ZIC3- related heterotaxy. In order to identify novel genetic causes of heterotaxy, array-based single nucleotide polymorphism (SNP) and comparative genomic hybridization (CGH) screens for copy number variation (CNVs) were completed in a large and carefully phenotyped cohort of 225 patients with heterotaxy and CHDs. Identified CNVs with pathogenic potential ranged in size from large unbalanced translocations to smaller, kilobase-scale abnormalities. Over 35 rare CNVs were found to encompass 165 genes of possible interest as heterotaxy candidates. Top candidates were screened for L-R patterning functions by morpholino loss of function experiments in Xenopus laevis. We describe results from these analyses and identify the platelet isoform of phosphofructokinase-1 (PFKP) as a novel genetic cause of heterotaxy. Results from these studies collectively confirm a high yield for array-based testing of patients with heterotaxy, and support use of these technologies for identification of novel causative genes. ii Previous genetic analyses have suggested that nearly 75% of all X-linked familial and 1% of all sporadic heterotaxy cases can be attributed to mutations in ZIC3. To date, most reported mutations have been identified in five tandemly repeated zinc finger domains in the first two exons. Many of these mutations have demonstrated functional consequences in ZIC3 nuclear transactivation and subcellular localization. The pathogenic potentials of flanking N- and C- terminal mutations are, however, less certain. Therefore, in order to further define the functional significance of mutations occurring throughout the ZIC3 gene, the full ZIC3 coding region and associated splice junctions was sequenced in a cohort of 440 unrelated patients with assorted situs anomalies and CHDs. Of the 11 mutations identified, 8 were novel, including 5 occurring in non-zinc finger domains. For functional studies, we supplemented these 11 mutations with 4 previously reported variants of uncertain significance. Aberrant cytoplasmic shuttling and decreased luciferase reporter transactivation were observed for all mutations affecting zinc finger domains but not for mutations in terminal regions. Results from these analyses significantly expanded the ZIC3 mutation spectrum, supported a higher than expected mutation yield in patients with sporadic heterotaxy (3.8% vs. 1% overall; 5.2% in affected males), and suggested alternative pathogenic mechanisms for mutations affecting non-zinc finger domains. iii iv DEDICATION: To my friends and family for their love and support. To Michael Hester, Kristin Bell, and Thomas Acciani for their Thursdays and Wednesdays. And to the Prog Gods for all that they do. I may never find all the answers. I may never understand why. I may never prove what I know to be true, But I know that I still have to try. Dream Theater Metropolis Pt. 2: Scenes from a Memory v Table of Contents ABSTRACT .................................................................................................................................................. ii CHAPTER 1: Introduction ........................................................................................................................... 1 1.1. THE HETEROTAXY CLINICAL SPECTRUM .............................................................................. 1 1.2. HETEROTAXY AND CONGENITAL HEART DISEASE ............................................................. 3 1.3. HETEROTAXY IS GENETICALLY HETEROGENEOUS ............................................................ 4 1.4. GENETIC TESTING FOR HETEROTAXY AND CONGENITAL HEART DEFECTS ............... 7 1.5. ZIC3 AS A GENETIC CAUSE OF HETEROTAXY ..................................................................... 10 1.5.1. The ZIC3 mutation spectrum .................................................................................................... 10 1.5.2. ZIC3 expression and function ................................................................................................... 12 1.5.3. ZIC3 structure ........................................................................................................................... 14 1.6. THE MOLECULAR MECHANISMS OF LEFT-RIGHT PATTERNING .................................... 16 1.6.1. The node, cilia, and nodal flow ................................................................................................. 17 1.6.2. Nodal signaling ......................................................................................................................... 22 1.6.3. Flux or flow? ............................................................................................................................. 24 1.7. XENOPUS AS A MODEL SYSTEM FOR STUDYING HETEROTAXY ................................... 25 1.8. EXPERIMENTAL RATIONALE AND SUMMARY OF MAJOR FINDINGS ............................ 26 1.9. FIGURES ......................................................................................................................................... 29 Figure 1.9.1. ZIC3 structure ................................................................................................................ 29 1.10. REFERENCES .............................................................................................................................. 30 CHAPTER 2: Copy number variation as a genetic basis for heterotaxy and heterotaxy-spectrum congenital heart defects ............................................................................................................................... 48 2.1. ABSTRACT ..................................................................................................................................... 48 2.2. INTRODUCTION ........................................................................................................................... 49 2.3. MATERIALS AND METHODS ..................................................................................................... 53 2.3.1. Patient recruitment and phenotypic classification ..................................................................... 53 2.3.2. Chromosome microarray analysis (CMA) ................................................................................ 54 2.3.3. CNV prioritization .................................................................................................................... 55 2.3.4. In vitro fertilization and Xenopus laevis embryo staging .......................................................... 56 2.3.5. Morpholino design .................................................................................................................... 56 2.3.6. pfkp and pitrm1 knockdown ...................................................................................................... 57 2.3.7. Synergy and rescue ................................................................................................................... 58 2.3.8. Left-right marker analyses ........................................................................................................ 59 vi 2.4. RESULTS ........................................................................................................................................ 60 2.4.1. Genetic analyses of patients with heterotaxy identify rare copy number variants .................... 60 2.4.2. Knockdown of pfkp results in left-right patterning defects in Xenopus laevis .......................... 62 2.5. DISCUSSION .................................................................................................................................. 65 2.5.1. Copy number variant analyses identify novel heterotaxy gene candidates ............................... 65 2.5.2. PFKP as a novel cause of heterotaxy
Load more

Recommended publications
  • Browsing Genes and Genomes with Ensembl
    The Bioinformatics Roadshow Copenhagen, Denmark 16 & 17 June 2011 BROWSING GENES AND GENOMES WITH ENSEMBL EXERCISES AND ANSWERS Note: These exercises are based on Ensembl version 62 (13 April 2011). After in future a new version has gone live, version 62 will still be available at http://e62.ensembl.org. If your answer doesn’t correspond with the given answer, please consult the instructor. ______________________________________________________________ BROWSER ______________________________________________________________ Exercise 1 – Exploring a gene (a) Find the human F9 (Coagulation factor IX) gene. On which chromosome and which strand of the genome is this gene located? How many transcripts (splice variants) have been annotated for it? (b) What is the longest transcript? How long is the protein it encodes? How many exons does it have? Are any of the exons completely or partially untranslated? (c) Have a look at the external references for ENST00000218099. What is the function of F9? (d) Is it possible to monitor expression of ENST00000218099 with the CodeLink microarray? If so, can it also be used to monitor expression of the other two transcripts? (e) In which part (i.e. the N-terminal or C-terminal half) of the protein encoded by ENST00000218099 does its peptidase activity, responsible for the cleavage of factor X to yield its active form factor Xa, reside? (f) How many non-synonymous variants have been discovered for the protein encoded by ENST00000218099? (g) Is there a mouse ortholog predicted for the human F9 gene? (h) On which cytogenetic band and on which contig is the F9 gene located? Is there a BAC clone that contains the complete F9 gene? (i) If you have yourself a gene of interest, explore what information Ensembl displays about it! ______________________________________________________________ Answer (a) Go to the Ensembl homepage (http://www.ensembl.org).
    [Show full text]
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • New Approaches to Functional Process Discovery in HPV 16-Associated Cervical Cancer Cells by Gene Ontology
    Cancer Research and Treatment 2003;35(4):304-313 New Approaches to Functional Process Discovery in HPV 16-Associated Cervical Cancer Cells by Gene Ontology Yong-Wan Kim, Ph.D.1, Min-Je Suh, M.S.1, Jin-Sik Bae, M.S.1, Su Mi Bae, M.S.1, Joo Hee Yoon, M.D.2, Soo Young Hur, M.D.2, Jae Hoon Kim, M.D.2, Duck Young Ro, M.D.2, Joon Mo Lee, M.D.2, Sung Eun Namkoong, M.D.2, Chong Kook Kim, Ph.D.3 and Woong Shick Ahn, M.D.2 1Catholic Research Institutes of Medical Science, 2Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul; 3College of Pharmacy, Seoul National University, Seoul, Korea Purpose: This study utilized both mRNA differential significant genes of unknown function affected by the display and the Gene Ontology (GO) analysis to char- HPV-16-derived pathway. The GO analysis suggested that acterize the multiple interactions of a number of genes the cervical cancer cells underwent repression of the with gene expression profiles involved in the HPV-16- cancer-specific cell adhesive properties. Also, genes induced cervical carcinogenesis. belonging to DNA metabolism, such as DNA repair and Materials and Methods: mRNA differential displays, replication, were strongly down-regulated, whereas sig- with HPV-16 positive cervical cancer cell line (SiHa), and nificant increases were shown in the protein degradation normal human keratinocyte cell line (HaCaT) as a con- and synthesis. trol, were used. Each human gene has several biological Conclusion: The GO analysis can overcome the com- functions in the Gene Ontology; therefore, several func- plexity of the gene expression profile of the HPV-16- tions of each gene were chosen to establish a powerful associated pathway, identify several cancer-specific cel- cervical carcinogenesis pathway.
    [Show full text]
  • In Silico Analysis Identifies Genes Common Between Five Primary Gastrointestinal Cancer Sites with Potential Clinical Applications
    ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-14 In silico analysis identifies genes common between five primary gastrointestinal cancer sites with potential clinical applications Subhankar Chakraborty University of Nebraska Medical Center, Omaha, NE, USA Abstract Background Previous studies have investigated differential gene expression in gastrointes- tinal (GI) epithelial cancers by microarray. The aim of the present study was to use data from the Oncomine database to identify genes that share a similar differential expression in two or more primary GI cancer sites. Methods Five thousand of the most differentially expressed genes in epithelial cancers (com- pared to normal tissue) arising in the pancreas, liver, stomach, esophagus or colorectum were identified (1,000 per primary site) from Oncomine. Using Venn diagrams, genes common to two or more primary GI sites were identified. Functional and pathway analysis was performed on genes that were similarly expressed in ≥3 of the five areas of the GI tract. Results Forty six studies comprising 5,876 samples were included. Overall, 90.6% genes were unique to the respective primary sites, 7.4% shared between two GI primary sites, 1.8% between three and 0.2% between four GI primary sites. Pancreatic and hepatocellular cancers (HCC) shared most number of upregulated genes (N=66) while HCC and gastric cancer shared most downregulated genes (N=59). Genes encoding enzymes comprised the most commonly shared genes between GI primary sites (30.4% of upregulated and 63.2% of downregulated genes). Those genes that were shared between three or more GI primary sites also showed significant differential expression in the same direction in other non-GI cancers.
    [Show full text]
  • The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc Oncogenesis
    The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc oncogenesis By Yuting Sun This thesis is submitted in fulfilment of the requirements for the degree of Doctor of Philosophy at the University of New South Wales Children’s Cancer Institute Australia for Medical Research School of Women’s and Children’s Health, Faculty of Medicine University of New South Wales Australia August 2014 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Sun First name: Yuting Other name/s: Abbreviation for degree as given in the University calendar: PhD School : School of·Women's and Children's Health Faculty: Faculty of Medicine Title: The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc oncogenesis. Abstract 350 words maximum: (PLEASE TYPE) N-Myc Induces neuroblastoma by regulating the expression of target genes and proteins, and N-Myc protein is degraded by Fbxw7 and NEDD4 and stabilized by Aurora A. The class lla histone deacetylase HDAC5 suppresses gene transcription, and blocks myoblast and leukaemia cell differentiation. While histone H3 lysine 4 (H3K4) trimethylation at target gene promoters is a pre-requisite for Myc· induced transcriptional activation, WDRS, as a histone H3K4 methyltransferase presenter, is required for H3K4 methylation and transcriptional activation mediated by a histone H3K4 methyltransferase complex. Here, I investigated the roles of HDAC5 and WDR5 in N-Myc overexpressing neuroblastoma. I have found that N-Myc upregulates HDAC5 protein expression, and that HDAC5 represses NEDD4 gene expression, increases Aurora A gene expression and consequently upregulates N-Myc protein expression in neuroblastoma cells.
    [Show full text]
  • Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis
    Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis Deepti Verma, Anna-Karin Ekman, Cecilia Bivik Eding and Charlotta Enerbäck The self-archived postprint version of this journal article is available at Linköping University Institutional Repository (DiVA): http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-147791 N.B.: When citing this work, cite the original publication. Verma, D., Ekman, A., Bivik Eding, C., Enerbäck, C., (2018), Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis, Journal of Investigative Dermatology, 138(5), 1088-1093. https://doi.org/10.1016/j.jid.2017.11.036 Original publication available at: https://doi.org/10.1016/j.jid.2017.11.036 Copyright: Elsevier http://www.elsevier.com/ Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis Deepti Verma*a, Anna-Karin Ekman*a, Cecilia Bivik Edinga and Charlotta Enerbäcka *Authors contributed equally aIngrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Division of Dermatology, Linköping University, Linköping, Sweden Corresponding author: Charlotta Enerbäck Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Linköping University SE-581 85 Linköping, Sweden Phone: +46 10 103 7429 E-mail: [email protected] Short title Differential methylation in psoriasis Abbreviations CGI, CpG island; DMS, differentially methylated site; RRBS, reduced representation bisulphite sequencing Keywords (max 6) psoriasis, epidermis, methylation, Wnt, susceptibility, expression 1 ABSTRACT Psoriasis is a chronic inflammatory skin disease with both local and systemic components. Genome-wide approaches have identified more than 60 psoriasis-susceptibility loci, but genes are estimated to explain only one third of the heritability in psoriasis, suggesting additional, yet unidentified, sources of heritability.
    [Show full text]
  • Contribution of Enhancer-Driven and Master-Regulator Genes to Autoimmune Disease Revealed Using Functionally Informed SNP-To-Gene Linking Strategies Kushal K
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.02.279059; this version posted March 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Contribution of enhancer-driven and master-regulator genes to autoimmune disease revealed using functionally informed SNP-to-gene linking strategies Kushal K. Dey1, Steven Gazal1, Bryce van de Geijn 1,3, Samuel Sungil Kim 1,4, Joseph Nasser5, Jesse M. Engreitz5, Alkes L. Price 1,2,5 1 Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA 2 Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 3 Genentech, South San Francisco, CA 4 Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 5 Broad Institute of MIT and Harvard, Cambridge, MA, USA Abstract Gene regulation is known to play a fundamental role in human disease, but mechanisms of regulation vary greatly across genes. Here, we explore the con- tributions to disease of two types of genes: genes whose regulation is driven by enhancer regions as opposed to promoter regions (Enhancer-driven) and genes that regulate many other genes in trans (Master-regulator). We link these genes to SNPs using a comprehensive set of SNP-to-gene (S2G) strategies and apply stratified LD score regression to the resulting SNP annotations to draw three main conclusions about 11 autoimmune diseases and blood cell traits (average Ncase=13K across 6 autoimmune diseases, average N=443K across 5 blood cell traits).
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Alt Haplotypes Refseq Curated Sequences Snps Dnase Clusters
    Scale 50 Mb hg19 chr13: 50,000,000 100,000,000 Haplotypes to GRCh37 Reference Sequence Patches to GRCh37 Reference Sequence gl582975.1 Reference Assembly Alternate Haplotype Sequence Alignments Alt Haplotypes UCSC Genes (RefSeq, GenBank, CCDS, Rfam, tRNAs & Comparative Genomics) LINC00417 RNF17 MEDAG U6 U6 ESD NEK5 7SK PCDH9 MZT1 RBM26 MIR4500 GPC6 7SK DAOA ING1 DQ586768 RNF17 HSPH1 ALG5 DGKH ESD NEK3 DIAPH3 PCDH9 BORA RBM26 SLITRK5 GPC6 ZIC5 DAOA ING1 DQ579288 CENPJ HSPH1 ALG5 DGKH MED4 PRR20D PCDH9 BORA RBM26 SLITRK5 GPC6 ZIC2 DAOA ING1 DQ587539 CENPJ HSPH1 ALG5 DGKH MED4 PRR20D PCDH9 BORA RBM26 SLITRK5 DCT PCCA LIG4 F7 ANKRD20A9P CENPJ HSPH1 POSTN LACC1 RB1 PRR20D BC042366 BORA RBM26 LINC00433 DCT PCCA LIG4 F7 BC035261 CENPJ HSPH1 POSTN LACC1 RB1 PRR20B U7 DIS3 RBM26 LINC00353 DZIP1 FGF14 LIG4 F7 DQ572285 CENPJ HSPH1 POSTN SERP2 EBPL PRR20E PCDH9-AS2 DIS3 RBM26 LINC00559 OXGR1 TPP2 LIG4 F7 LINC00442 AMER2 RXFP2 UFM1 SERP2 EBPL PCDH17 PCDH9 DIS3 NDFIP2 MIR622 OXGR1 BIVM LIG4 F10 RNU6-52P AMER2 RXFP2 UFM1 TRNA BCMS PCDH17 LINC00550 UCHL3 SLITRK1 U6 OXGR1 BIVM LIG4 F10 TUBA3C AMER2 FRY UFM1 GTF2F2 BCMS PCDH17 KLHL1 LMO7 LINC00351 GPC5 IPO5 DAOA ING1 ANKRD26P3 RNF6 FRY FREM2 KCTD4 BCMS DIAPH3 KLHL1 LMO7 SLITRK6 Y_RNA IPO5 DAOA ING1 LINC00421 RNF6 FRY FREM2 KCTD4 BCMS DIAPH3 ATXN8OS LMO7 SLITRK6 5S_rRNA PCCA ABHD13 F10 TPTE2 RNF6 FRY NHLRC3 TPT1 BCMS DIAPH3 Y_RNA IRG1 MIR4500HG TRNA GGACT ABHD13 GRK1 TPTE2 RNF6 ZAR1L NHLRC3 TPT1 BCMS DIAPH3 LINC00348 IRG1 BC038529 MBNL2 BIVM MYO16 TPTE2 RNF6 BRCA2 NHLRC3 TPT1 BCMS DIAPH3 DACH1 CLN5 LINC00410
    [Show full text]
  • Human Astrocytes: Structure and Functions in the Healthy Brain
    Brain Struct Funct DOI 10.1007/s00429-017-1383-5 REVIEW Human astrocytes: structure and functions in the healthy brain Flora Vasile1 · Elena Dossi1 · Nathalie Rouach1 Received: 4 November 2016 / Accepted: 6 February 2017 © The Author(s) 2017. This article is published with open access at Springerlink.com Abstract Data collected on astrocytes’ physiology in the Introduction rodent have placed them as key regulators of synaptic, neu- ronal, network, and cognitive functions. While these find- Since the early discovery that the range of astroglial func- ings proved highly valuable for our awareness and appreci- tions extends considerably beyond passive structural sup- ation of non-neuronal cell significance in brain physiology, port, astrocytes have cemented their position as crucial early structural and phylogenic investigations of human determinants of proper neuronal function. Astrocytes are astrocytes hinted at potentially different astrocytic proper- now considered as full-fledged participants in brain cir- ties. This idea sparked interest to replicate rodent-based cuitry and processing, and display a large spectrum of studies on human samples, which have revealed an analo- functions at the cell level, such as the formation, matura- gous but enhanced involvement of astrocytes in neuronal tion and elimination of synapses, ionic homeostasis, clear- function of the human brain. Such evidence pointed to a ance of neurotransmitters, regulation of extracellular space central role of human astrocytes in sustaining more com- volume, and modulation of synaptic activity and plastic- plex information processing. Here, we review the current ity (Araque et al. 2014; Dallérac and Rouach 2016). It has state of our knowledge of human astrocytes regarding their additionally been demonstrated that they are involved in structure, gene profile, and functions, highlighting the dif- rhythm generation and neuronal network patterns (Fellin ferences with rodent astrocytes.
    [Show full text]